Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors

NCT04622774 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT04622774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04622774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 29, 2020
Completion date
December 28, 2023
Enrollment
56 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor